Skip to main content
Clinical Trials/NCT06251999
NCT06251999
Not yet recruiting
Phase 4

Efficacy and Safety of Fospropofol Disodium Sedation for Same-day Bidirectional Endoscopy in Elderly Patients: a Prospective, Single-center, Randomized, Double-blind, Non-inferiority Trial

Shanghai 6th People's Hospital0 sites256 target enrollmentAugust 1, 2024

Overview

Phase
Phase 4
Intervention
fospropofol sedation
Conditions
Elderly Patients
Sponsor
Shanghai 6th People's Hospital
Enrollment
256
Primary Endpoint
The success rate of same-day bidirectional endoscopy
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Introduction: Fospropofol disodium is a novel prodrug that has improved pharmacokinetic and pharmacodynamic properties compared with propofol. This trial aims to compare the efficacy and safety of fospropofol versus propofol sedation for same-day bidirectional endoscopy in elderly patients.

Methods and analysis: This is a prospective, single-center, double-blind, randomized, propofol-controlled, non-inferiority trial. A total of 256 adult patients scheduled for same-day bidirectional endoscopy under sedation will be randomly allocated, in a 1:1 ratio, to a fospropofol group or a propofol group (n=128 in each group). All patients will receive analgesic pretreatment with sufentanil 5 μg. Two minutes later, an initial bolus dose of fospropofol 6.5 mg/kg or 1.5 mg/kg propofol and supplemental doses of fospropofol 1.6 mg/kg or 0.5 mg/kg propofol will be titrated as needed to the target sedation levels during the procedures. The primary outcome is the success rate of same-day bidirectional endoscopy. Secondary outcomes include the time to successful induction of sedation, duration, time to being fully alert, time to patient discharge, endoscopist satisfaction, patient satisfaction, and the top-up frequency and dosage of sedative medications. The safety endpoints consist of adverse events (AEs) concerning cough reflex, gag reflexes, body movement, muscular tremor, pain on injection. Sedation-related AEs, including episodes of desaturation, severe desaturation (SpO2 < 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia, will be also recorded. Data will be analyzed on the intention-to-treat basis.

Discussion: The investigators hypothesize that the efficacy and safety of fospropofol sedation for elderly patients undergoing same-visit bidirectional endoscopy will not be inferior to that of propofol. The findings will provide daily practice of sedation regimens for same-day bidirectional endoscopy in elderly patients.

Registry
clinicaltrials.gov
Start Date
August 1, 2024
End Date
August 31, 2028
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xiaofeng WANG

Principal investigator

Shanghai 6th People's Hospital

Eligibility Criteria

Inclusion Criteria

  • 65 years or older
  • American Society of Anesthesiologists (ASA) physical status I to III
  • Body mass index (BMI) 18-30 kg/m2
  • Scheduled for same-day bidirectional endoscopy under sedation

Exclusion Criteria

  • Severe cardiovascular, pulmonary, renal, or liver diseases
  • Previous hypotension (systolic blood pressure ≤90 mmHg), bradycardia (heart rate \<50 beats/min), or hypoxemia (SpO2 \<90%)
  • Neurocognitive or psychiatric disorders
  • Contraindications to gastroscopy (gastric retention, long-term aspirin administration, etc.)
  • Hypersensitivity to study medications
  • Drug or alcohol misuse
  • Definite upper respiratory tract infection
  • Refusal for participation

Arms & Interventions

fospropofol

Intervention: fospropofol sedation

propofol

Intervention: Propofol

Outcomes

Primary Outcomes

The success rate of same-day bidirectional endoscopy

Time Frame: Immediate time after sedation emergence

The success rate of the gastrointestinal endoscopy was assessed according to the following criteria : 1) completion of the gastrointestinal endoscopy; 2) no need for rescue sedative/anesthetic, which means the top-up doses of the experimental drugs were administered no more than five times within any 15-min window from the initial administration to the end of the procedure.

Secondary Outcomes

  • Incidence of adverse events (AEs) at timepoint 2(Intraoperative (during sedation))
  • Incidence of adverse events (AEs) at timepoint 3(Intraoperative (the timepoint of sedation emergence))
  • Incidence of adverse events (AEs) at timepoint 6(Immediate time of hospital discharge)
  • The time to successful induction of sedation(Immediate time after sedation emergence)
  • Time to being fully alert(Immediate time after sedation emergence)
  • Time to patient discharge(Immediate time of hospital discharge)
  • Endoscopist's satisfaction questionnaire(Immediate time after sedation procedure completion)
  • Patient's satisfaction questionnaire(Immediate time of hospital discharge)
  • The top-up frequency and dosage of sedative medications(Immediate time after sedation emergence)
  • Incidence of adverse events (AEs) at timepoint 1(baseline (Prior to sedation))
  • Incidence of adverse events (AEs) at timepoint 4(15 min in post-anesthesia care unit)
  • Incidence of adverse events (AEs) at timepoint 5(30 min in post-anesthesia care unit)

Similar Trials